Treatment and non-treatment related ocular manifestations in patients with chronic hepatitis B or C

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 8, 2013, Pages 1123-1131

  Tsoumani, A ^a   Theopistos, V ^a   Katsanos, K ^a   Asproudis, I ^a   Tsianos, E V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Eye; Hepatitis B.; Hepatitis C.; Interferon; Ocular manifestations

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT ALPHA INTERFERON; RETINA S ANTIGEN; RIBAVIRIN;

ANTERIOR EYE SEGMENT; ANTERIOR ISCHEMIC OPTIC NEUROPATHY; ARTICLE; CENTRAL VEIN THROMBOSIS; CORNEA RODENT ULCER; CRYOGLOBULINEMIA; DIPLOPIA; DRUG WITHDRAWAL; DRY EYE; EYELID DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; KERATOPATHY; MONOTHERAPY; MYASTHENIA; MYASTHENIA GRAVIS; NEUROPATHY; NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY; NONHUMAN; OPHTHALMOSCOPY; OPTIC NERVE DISEASE; PATIENT CARE; PERIPHERAL ULCERATIVE KERATOPATHY; PIGMENT EPITHELIUM; POSTERIOR EYE SEGMENT; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINOPATHY; SCLERITIS; SJOEGREN SYNDROME; SUBCAPSULAR CATARACT; THROMBOSIS; TRICHOMEGALY; UVEITIS; VACCINATION; VASCULITIS; VOGT KOYANAGI SYNDROME; XEROPHTHALMIA;

DRY EYE SYNDROMES; EYE DISEASES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS;

EID: 84878526904     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. INSTITUTE OF MEDICINE REPORT ON VIRAL HEPATITIS. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C (January 2010, downloaded from http://www.nap.edu/catalog/12793.html)
2. Lavanchy, D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008; 22: 991-1008.
3. ZIGNEGO AL, PILUSO A, GIANNINI C. HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation. Autoimmun Rev 2008; 8: 107-111.
4. PYRSOPOULOS NT, REDDY KR. Extrahepatic manifestations of chronic viral hepatitis. Curr Gastroenterol Rep 2001; 3: 71-78.
5. ZEGANS ME, ANNINGER W, CHAPMAN C, GORDON SR. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002; 13: 423-427.
6. FRAUNFELDER FW, SUHLER EB, FRAUNFELDER FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol 2010; 29: 26-29.
7. CACOUB P, RENOU C, ROSENTHAL E, COHEN P, LOURY I, LOUSTAUD-RATTI V, YAMAMOTO AM, CAMPROUX AC, HAUSFATER P, MUSSET L, VEYSSIER P, RAGUIN G, PIETTE JC THE GERMIVIC. GROUPE D'ETUDE ET DE RECHERCHE EN MEDECINE INTERNE ET MALADIES. Infectieuses sur le Virus de l'Hepatite C, Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine (Baltimore) 2000; 79: 47-56.
8. FOX RI, STERN M, MICHELSON P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000; 12: 391-398.
9. GUMUS K, YURCI A, MIRZA E, ARDA H, ONER A, TOPAKTAS D, KARAKUCUK S. Evaluation of ocular surface damage and dry eye status in chronic hepatitis C at different stages of hepatic fibrosis. Cornea 2009; 28: 997-1002.
10. JACOBI C, WENKEL H, JACOBI A, KORN K, CURSIEFEN C, KRUSE FE. Hepatitis C and ocular surface disease. Am J Ophthalmol 2007; 144: 705-711.
11. ABE T, NAKAJIMA A, MATSUNAGA M, ET AL. Decreased tear lactoferrin concentration with chronic hepatitis C. Br J Ophthalmol 1999; 83: 684-687.
12. HUANG FC, SHIH MH, TSENG SH, LIN SC, CHANG TT. Tear function changes during interferon and ribavirin treatment in patients with chronic hepatitis C. Cornea 2005; 24: 561-566.
13. COTLER SJ, WARTELLE CF, LARSON AM, GRETCH DR, JENSEN DM, CARITHERS RL JR. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000; 7: 211-217.
14. WILSON SE, LEE WM, MURAKAMI C, WENG J, MONINGER GA. Mooren's corneal ulcer and hepatitis virus infection. (letter) N Engl J Med 1993; 329: 62.
15. WILSON SE, LEE WM, MURAKAMI C, WENG J, MONINGER GA. Mooren's type hepatitis C virus associated corneal ulceration. Ophthalmology 1994; 101: 736-745.
16. CUNNINGHAM JR ET, WILSON SE. Link between Mooren's ulcer, hepatitis C is questioned. Associated flaviviruses could cause corneal problems, yet go undetected by available tests. Ocular Surgery News. 15 January, 2000.
17. PLUZNIK DANIEL, BUTRUS SALIM I. Hepatitis C-Associated Peripheral Corneal Ulceration: Rapid Response to Intravenous Steroids Cornea 2001; 20: 888-889.
18. MOAZAMI G, AURAN JD, FLORAKIS GJ, WILSON SE, SRINIVASAN DB. Interferon treatment of Mooren's ulcers associated with hepatitis C. Am J Ophthalmol 1995; 119: 365-366.
19. JAIN AK, SUKHIJA J, SAINI JS, CHAWLA Y, DHIMAN RK. Hepatitis C virus-associated keratitis. Eye (Lond) 2004; 18: 131-134.
20. FEUCHT H, POLYWKA S, ZOLLNER B, LAUFS R. Greater amount of HCV-RNA in tear compared to blood. Microbiol Immunol 1994; 38: 157-158.
21. HOUGHTON M, WEINER A, HAN J, KUO G, CHOO QL. Molecular biology of the hepatitis C virus: implications of diagnosis, development and control of viral diseases. Hepatology 1991; 14: 381-388.
22. KEDHAR SR, BELAIR ML, JUN AS, SULKOWSKI M, THORNE JE Scleritis and peripheral ulcerative keratitis with hepatitis C virus-related cryoglobulinemia. Arch Ophthalmol 2007; 125: 852-853.
23. KU JY, SHARMA A. Pegylated interferon and ribavirin therapy for hepatitis C causing cataract. Clin Exp Ophthalmol 2009; 37: 743-745.
24. MEHRAN H. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 1945-1946.
25. IINO S. High dose interferon treatment in chronic hepatitis C. Gut 1993; 34: S114-118.
26. KADAYIFCILAR S, BOYACIOGLU S, KART H, GURSOY M, AYDIN P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 1999; 13: 241-246.
27. HERNANDEZ-NUNEZ A, FERNANDEZ-HERRERA J, BUCETA LR, GARCIA-DIEZ A. Trichomegaly following treatment with interferon alpha-2b. Lancet 2002; 359: 1107.
28. BERGLUND EF, BURTON GV, MILLS GM, NICHOLS GM. Hypertrichosis of the eyelashes associated with interferon-alpha therapy for chronic granulocytic leukemia. South Med J 1990; 83: 363.
29. OZDOGAN M, GUR G, KADAYIFCILAR S, BOYACIOGLU S, OZGUR O, TELETAR H. An unusual adverse effect of interferon: hypertrichosis of the eyelashes. J. Interferon Cytokine Res 2000; 20: 633-634.
30. FOON KA, ROTH MS, BUNN PA JR. Interferon therapy of non- Hodgkin's lymphoma. Cancer 1987; 59: 601-604.
31. SACCHI S, KANTARJIAN H, O'BRIEN S, COHEN PR, PIERCE S, TALPAZ M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401-2407.
32. ARIYOSHI K, SHINOHARA K, RUIRONG X. Growth of eyebrow after alpha interferon administration. Am J Hematol 1996; 53: 50-51.
33. WEEGINK CJ, CHAMULEAU RA, REESINK HW, MOLENAAR DS. Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. J Gastroenterol 2001; 36: 723-724.
34. BORGIA G, REYNAUD L, GENTILE I, CERINI R, CIAMPI R, DELLO RUSSO M, PIAZZA M. Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 469-470.
35. KANG HM, PARK MJ, HWANG JM, KIM JW, JEONG SH. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis c. Korean J Hepatol 2009; 15: 209-215.
36. ABE T, SAKURAGI S, KURAMITSU OT. Retinopathy associated with hepatitis C virus. Jpn J Clin Ophthalmol (Rinsho Ganka) 1993; 47: 297-300.
37. ABE T, NAKAJIMA A, SATOH N, SATOH N, KOIZUMI T, SAKURAGI S, ONO T, KOMATSU M, MASAMUNE O. Clinical characteristics of hepatitis C virus associated retinopathy. Jpn J Ophthalmol 1995; 39: 411-419.
38. Myers JP, Di Bisceglie AM, Mann ES: Cryoglobulinemia associated with Purtscher-like retinopathy. Am J Ophthalmol 2001; 131: 802-804.
39. AGNELLO V, CHUNG RT, KAPLAN LM: A role for hepatitis C virus infection in type II cryglobulinemia. N Engl J Med 1992; 327: 1490-1495.
40. IKEBE T, NAKATSUKA K, GOTO M, SAKAI Y, KAGEYAMA S. A CASE OF RETINOPATHY INDUCED BY INTRA venous administration of interferon. Folia Ophthalmol Jpn (Ganka-Kiyo) 1990; 41: 2291-2296.
41. KAWANO T, SHIGEHIRA M, UTO H, NAKAMA T, KATO J, HAYASHI K, MARUYAMA T, KURIBAYASHI T, CHUMAN T, FUTAMI T, TSUBOUCHI H. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91: 309-313.
42. SAITO H, EBINUMA H, NAGATA H, INAGAKI Y, SAITO Y, WAKABAYASHI K, TAKAGI T, NAKAMURA M, KATSURA H, OGUCHI Y, ISHII H. Interferon-associated retinopathy in a uniform regimen of natural interferon-alpha therapy for chronic hepatitis C. Liver 2001; 21: 192-197.
43. HAYASAKA S, NAGAKI Y, MATSUMOTO M, SATO S. Interferon associated retinopathy. Br J Ophthalmol 1998; 82: 323-325.
44. FOUAD YM, KHALAF H, IBRAHEEM H, RADY H, HELMY AK. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin. Int J Infect Dis 2012; 16: e67-71.
45. HAYASAKA S, FUJII M, YAMAMOTO Y, NODA S, KUROME H, SASAKI M. Retinopathy and sub-conjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995; 79: 150-152.
46. SCHULMAN JA, LIANG C, KOORAGAYALA LM, KING J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003; 110: 437-442.
47. CUTHBERTSON FM, DAVIES M, MCKIBBIN M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004; 88: 1518-1520.
48. JAIN K, LAM WC, WAHEEB S, THAI Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85: 1171-1173.
49. CHISHOLM JA, WILLIAMS G, SPENCE E, PARKS S, KEATING D, GAVIN M, MILLS PR. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Aliment Pharmacol Ther 2005; 21: 723-732.
50. OKUSE C, YOTSUYANAGI H, NAGASEY, KOBAYASHI Y, YASUDA K, KOIKE K, IINO S, SUZUKI M, ITOH F. Risk factors for retinopathy associated with interferon aα-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12: 3756-3759.
51. WONG TY, KLEIN R, SHARRETT AR, MANOLIO TA, HUBBARD LD, MARINO EK, KULLER L, BURKE G, TRACY RP, POLAK JF, GOTTDIENER JS, SISCOVICK DS. The prevalence and risk factors of retinal microvascular abnormalities in older persons: the cardiovascular health study. Ophthalmology 2003; 110: 658-666.
52. NARKEWICZ MR, ROSENTHAL P, SCHWARZ KB, DRACK A, MARGOLIS T, REPKA MX; PEDS-C STUDY GROUP. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010; 51: 183-186.
53. SHIGEO SUGANO, TOKUYA SUZUKI, MANABU WATANABE, KENJI OHE, KUNIHIKO ISHII AND TUGIO OKAJIMA Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis. Am J Gastroenterol 1998; 93, 2441-2444.
54. TU KL, BOWYER J, SCHOFIELD K, HARDING S. Severe interferon associated retinopathy. Br J Ophthalmol 2003; 87: 247-248.
55. GUYER DR, TIEDEMAN J, YANNUZZI LA, SLAKTER JS, PARKE D, KELLEY J, TANG RA, MARMOR M, ABRAMS G, MILLER JW, ET AL. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111: 350-356.
56. NISHIWAKI H, OGURA Y, MIYAMOTO K, HIROSHIBA N, HAMADA M, HONDA Y. Prednisolone, platelet-activating factor receptor antagonist, or superoxide dismutase reduced leukocyte entrapment induced by interferon alpha in retinal microcirculation. Invest Ophthalmol Vis Sci 1997; 38: 811-816.
57. NISHIWAKI H, OGURA Y, MIYAMOTO K, MATSUDA N, HONDA Y. Interferon alfinduces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol 1996; 114: 726-730.
58. D' ALTEROCHE L, MAJZOUB S, LECUYER AI, DELPLACE MP, BACQ Y. Ophthalmologic side effects during alphainterferon therapy for viral hepatitis. J Hepatol 2006; 44: 56-61
59. WILSON R. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection. J Clin Gastroenterol 2004; 8: 717-722.
60. ZANDIEH I, ADENWALLA M, CHEONG-LEE C, MA EP, YOSHIDA EM. Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol 2006; 12: 4908-4910.
61. AKYUZ F, AKYUZ U, KOCAMAN O, KAYMAKOGLU S. Rare complication of interferon alpha therapy: retinal vein thrombosis. Acta Gastroenterol Belg 2005; 68: 394-395.
62. RUBIO JE JR, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina 2003; 23: 546-548.
63. NADIR A, AMIN A, CHALISA N, VAN THIEL DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat 2000; 7: 466-470.
64. RACHITSKAYA AV, LEE RK, DUBOVY SR, SCHIFF ER. Combined central retinal vein and central retinal artery occlusions and neovascular glaucoma associated with interferon treatment. Eur J Ophthalmol 2011; 22: 284-287.
65. SHETH HG, MICHAELIDES M, SIRIWARDENA D. Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis. Indian J Ophthalmol 2010; 58: 147-148.
66. TOKAI R, IKEDA T, MIYAURA T, SATO K. Interferon-associated retinopathy and cystoid macular oedema. Arch Ophthalmol 2001; 119: 1077-1079.
67. SHIMURA M, SAITO T, YASUDA K, TAMAI M. Clinical course of macular oedema in two cases of interferon-associated retinopathy observed by optical coherence tomography. Jpn J Ophthalmol 2005; 49: 231-234.
68. KABBAJ N, SENTISSI S, MOHAMMADI M, BENAÏSSA A, AMRANI N. Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitis C. Gastroenterol Clin Biol Epub 2009; 33: 115-117.
69. WEI YH, WANG IH, WOUNG LC, JOU JR. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immun Inflamm 2009; 17: 191-194.
70. SENE D, TOUITOU V, BODAGHI B, SAADOUN D, PERLEMUTER G, GASSOUX N, PIETTE JC, HOANG PL, CACOUB P. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.World J Gastoenterol 2007; 13: 3137-3140.
71. CHAN JW. Bilateral non arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C. Eye (Lond) 2007; 21; 877-878.
72. FODOR M, NAGY V, BERTA A, TORNAI I, PFIEGLER G. Hepatitis C virus presumably associated bilateral consecutive anterior ischemic optic neuropathy. Eur J Ophthalmol 2008; 18: 313-315.
73. MANESIS EK, MOSCHOS M, BROUZAS D, KOTSIRAS J, PETROU C, THEODASIADIS G, HADZIYANNIS S. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27: 1421-1427.
74. AL-MUAMMAR AM, AL-MUDHAIYAN TM, AL OTAIBI M, ABDO A, ABU EL-ASRAR AM. Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Int Ophthalmol 2010; 30: 611-613.
75. PAPASTATHOPOULOS K, BOUZAS E, NAOUM G, VERGADOS I, TSIODRAS S. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection. J Infect 2006; 52: e59-e61
76. SYLVESTRE DL, DISSTON AR, BUI DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 2003; 10: 467-470.
77. TOUITOU V, BODAGHI B, CASSOUX N, TRAN TH, RAO NA, CACOUB P, LEHOANG P. Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 2005; 140: 949-952.
78. KASAHARA A, HIRAIDE A, TOMITA N, IWAHASHI H, IMAGAWA A, OHGURO N, YAMAMOTO S, MITA E, HAYASHI N. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 2004; 39: 1106-1109.
79. CHEBIL A, KORT F, BOURAOUI R, YOUSSEF NB, EL MATRI L. Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection [Article in French]. J Fr Ophtalmol 2010; 33: 185-188.
80. SOMA M, HIRATA A, TAKAHASHI T, OKINAMI S. Relapse of Vogt-Koyanagi-Harada Disease during interferon-aα and ribavirin therapy in a case of chronic viral hepatitis C. Case Report Ophthalmol 2011; 2: 5-9.
81. TEMEL A, SEBER E, GUNAY M. Detection of hepatitis B surface antigen in aqueous humor. Acta Ophthalmol (Copenh) 1990; 68: 205-208.
82. KOKSAL I, CETINKAYA K, AKER F. Hepatitis B surface antigen in tears and aqueous humor: a comparative study of serum hepatitis B surface antigen levels. Ophthalmologica 1992; 204: 19-22.
83. TSAI CY, LIN CL, LIN SC, LIOU SW. Detection of hepatitis B virus in the aqueous humor of a hepatitis B virus carrier.Ophthalmologica 2009; 223: 93-95.
84. WANG TJ, WANG IJ, HU CC, LIN HC. Comorbidities of dry eye disease: a nationwide populationbased study. Acta Ophthalmol 2010 Aug 31 [Epub ahead of print].
85. CACOUB P, SAADOUN D, BOURLIÈRE M, KHIRI H, MARTINEAU A, BENHAMOU Y, VARASTET M, POL S, THIBAULT V, ROTILY M, HALFON P. Hepatitis B virus genotypes and extrahepatic manifestations. J Hepatol 2005; 43: 764-770.
86. ROH MI, KIM JH, BYEON SH, KOH HJ, LEE SC, KWON OW. Estimated prevalence and risk factor for agerelated maculopathy. Yonsei Med J 2008 31; 49: 931-941.
87. SLEPOVA OS, KUSHNIR VN, ZAYSEVA NS, TITARENKO ZD, DUMBRAVA VA. Clinical and immunological signs of retinal lesions and possibilities of their correction by drugs in patients with chronic diffuse liver diseases of viral etiology and carriers of Australia antigen.Vestn Oftalmol 1994; 110: 27-29.
88. SINGH VK, KALRA HK, YAMAKI K, ABE T, DONOSO LA, SHINOHARA TJ. Molecular mimicry between a uveitopathogenic site of S-antigen and viral peptides. Induction of experimental autoimmune uveitis in Lewis rats. Immunology 1990; 15: 1282-1287.
89. SHINOHARA T, SINGH VK, TSUDA M, YAMAKI K, ABE T, SUZUKI S. S-antigen: from gene to autoimmune uveitis.Exp Eye Res 1990; 50: 751-757.
90. GANGADHARAN B, ANTROBUS R, DWEK RA, ZITZMANN N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients Clin Chem 2007; 53: 1792-1799.
91. YATES JR, SEPP T, MATHARU BK, KHAN JC, THURLBY DA, SHAHID H, CLAYTON DG, HAYWARD C, MORGAN J, WRIGHT AF, ARMBRECHT AM, DHILLON B, DEARY IJ, REDMOND E, BIRD AC, MOORE AT; GENETIC FACTORS IN AMD STUDY GROUP. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 9: 553-561.
92. VINE AK, STADER J, BRANHAM K, MUSCH DC, SWAROOP A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 2005; 11: 2076-2080.
93. MURRAY PI, WAITE J, RAHI AH, TEDDER RS. Acute anterior uveitis and hepatitis B virus infection. Br J Ophthalmol 1984; 68: 595-597.
94. MURRAY PI, PRASAD J, RAHI HS. Status of hepatitis B virus in the aetiology of uveitis in Great Britain. Br J Ophthalmology 1983; 67: 685-687.
95. VOIGT U, BAUM U, BEHRENDT W, HEGEMANN S, TERBORG C, STROBEL J. Neuritis of the optic nerve after vaccinations against hepatitis A, hepatitis B and yellow fever. Klin Monbl Augenheilkd 2001; 218: 688-690.
96. ERGUVEN M, GUVEN S, AKYUZ U, BILGIÇ O, LALOGLU F. Optic neuritis following hepatitis B vaccination in a 9-year-old girl. J Chin Med Assoc 2009; 72: 594-597.
97. BRÉZIN AP, MASSIN-KOROBELNIK P, BOUDIN M, GAUDRIC A, LEHOANG P. Acute posterior multifocal placoid pigment epitheliopathy after hepatitis B vaccine. Arch Ophthalmol 1995; 113: 297-300.
98. HERROELEN L, DE KEYSER J, EBINGER G. Central-nervous-system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet 1991; 338: 1174-1175.
99. BREZIN AP, LAUTIER-FRAU M, HAMEDANI M, ROGEAUX O, LEHOANG P. Visual loss and eosinophilia after recombinant hepatitis B vaccine. Lancet 1993; 342: 563-564.
100. BAGLIVO E, SAFRAN AB, BORRUAT FX. Multiple evanescent white dot syndrome. Am J Ophthalmol 1996; 122: 431-432.
101. BERKMAN N. A case of segmentary unilateral occlusion of the central retinal vein following hepatitis B vaccination. Presse Med 1997; 26: 670.
102. GRANEL B, DISDIER P, DEVIN F, SWIADER L, RISS JM, COUPIER L, HARLÉ JR, JOUGLARD J, WEILLER PJ. Occlusion of the central retinal vein after vaccination against viral hepatitis B with recombinant vaccines. 4 cases. Presse Med 1997; 26: 62-65.
103. DEVIN F, ROQUES G, DISDIER P, RODOR F, WEILLER PJ. Occlusion of central retinal vein after hepatitis B vaccination. Lancet 1996 8; 347: 1626.
104. FAREL C, SUZMAN DL, MCLAUGHLIN M, CAMPBELL C, KORATICH C, MASUR H, METCALF JA, ROBINSON MR, POLIS MA, KOTTILIL S. Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2a and ribavirin. AIDS 2004; 18: 1805-1809.
105. PAZIENZA V. Ophthalmological complications in hepatitis C virus infection: side effect of interferon therapy or a direct role of HCV? Biomed Pharmacother 2011; 65: 317-318.